Case report shows improved TRPG and oxygen levels in a patient with interstitial pneumonia, suggesting inhaled treprostinil is effective for Group 3 PH.
Inhaled treprostinil is the first-choice drug for the treatment of Group 3 pulmonary hypertension (PH) associated with chronic lung disease. A 72-year-old man was diagnosed with interstitial pneumonia, and his respiratory symptoms had gradually worsened. Echocardiography revealed a maximum tricuspid regurgitation pressure gradient (TRPG) of 64 mmHg, and the patient was diagnosed with group 3 PH. Subsequently, he was admitted to the hospital with acute heart failure. Inhaled treprostinil was prescribed, his B-type natriuretic peptide level and maximum TRPG subsequently improved, and his oxygen requirement decreased. Treprostinil inhalation may be effective in treating patients with severe respiratory symptoms of interstitial pneumonia.
No takes yet. Share an insight, caveat, or question.
Otsuka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: